ReviewEndocrine connections2026
Prognostic factors evaluated in differentiated thyroid carcinomas.
Review in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Differentiated thyroid carcinoma includes papillary (PTC) and follicular thyroid carcinomas (FTC). The biological characteristics and prognostic factors of these two carcinomas differ significantly. PTC is generally diagnosed by cytology; large tumor size, clinical node metastasis, and gross extrathyroidal and extranodal tumor invasion are significant prognostic factors for disease recurrence-free survival (DFS) and cause-specific survival (CSS). Age is a very important prognostic factor. Young age affects only DFS, whereas old age is related to both DFS and CSS. Aggressive variants, such as tall cell and hobnail variants, high Ki-67 labeling index, and TERT promoter gene mutations, are pathological and molecular prognostic factors. FTC is generally diagnosed based on postoperative pathology. Old age and large tumor size are associated with poor prognosis. Importantly, FTC is classified as minimally invasive, encapsulated angioinvasive, and widely invasive, which are closely related to the prognosis. Recent studies have demonstrated that the grade of vascular invasion is an important prognostic factor, whereas capsular invasion is not, because widely invasive FTC with no vascular invasion has an excellent prognosis. Dynamic markers, such as thyroglobulin doubling rate, metastatic tumor volume-doubling rate, and immunological indicators, such as the neutrophil-to-lymphocyte ratio, are useful for predicting the prognosis and evaluating the effectiveness of treatments, such as radioactive iodine therapy and molecular targeted therapy for recurrent lesions. Clinicians should accurately evaluate the prognostic markers of PTC and FTC in the pre-, intra-, and postoperative phases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.